NextKidney’s New M&A Will Have Big Implications for HemodialysisNextKidney’s New M&A Will Have Big Implications for Hemodialysis

A new acquisition could be a vital component in the advancement of dialysis. Amsterdam, the Netherlands-based NextKidney said it acquired Dialyss Pte. LTD. for an undisclosed sum.

Singapore - based Dialyss specializes in innovative technologies for the sorbent-based regeneration of dialysate during (home) dialysis. The companies said the acquisition marks a major milestone towards the commercialization of the Neokidney, a portable sorbent-based hemodialysis device.

 The companies are now working on a first-in-human trial in Singapore. It will be followed by a European multi-center trial, and submission for CE mark scheduled in 2023. In a release, the companies said the device will be the world's smallest and most user-friendly and cost-effective home hemodialysis device, using only 4 liters of fluids per session. It is fully independent of water supply and drain, and can therefore be used by patients anytime and anywhere.

"I am happy we realized what was logical from the beginning, combining the strengths of the development teams in Singapore and Lausanne, creating one company with expert knowledge on high-quality medical device development with top-notch innovative sorbent technology," concludes John Stooker, CFO of NextKidney BV.